Back
FOXO4-DRI — research compound

FOXO4-DRI

Research

FOXO4-DRI is a cell-penetrating senolytic peptide studied for selectively inducing apoptosis (cell death) in senescent ("zombie") cells by disrupting the FOXO4-p53 interaction, an active area of aging and cellular-senescence research.

Not FDA-approved; sold for research use only.

Sort by
🌍Worldwide
ZenterexTop pick

Worldwide

COA / lab reports
£74.99
Shop with discount →
🇺🇸USA
Soma Chems

United States

Shop with discount →

Entirely animal data — no human studies

Every finding for FOXO4-DRI comes from mice — no human trial was found in this research pass.

Benefits

FOXO4-DRI is a cell-penetrating peptide designed to disrupt the interaction between FOXO4 and p53 inside senescent ("zombie") cells, causing p53 to exit the nucleus and trigger apoptosis (cell death) selectively in those senescent cells.

Landmark study (multiple mouse models — fast-aging progeroid mice, transgenic senescence-tracking mice, and naturally aged wild-type mice): treatment restored kidney function (via plasma urea/creatinine), normalized liver enzymes (AST) after chemotherapy-drug exposure, and improved physical fitness measures (fur density, running-wheel activity) in aged mice. Baar et al., Cell, 2017 A separate study found FOXO4-DRI improved age-related testosterone insufficiency in aged mice by targeting senescent testicular (Leydig) cells.

This is genuinely well-regarded foundational senescent-cell biology research — but it is exclusively mouse data. Human translation is, as the original paper's authors themselves note, unstudied.

Dosage

No human dose exists. Mouse studies used various administration protocols across different aging/senescence models — not directly convertible to a human dosing regimen.

Side Effects

No human safety data exists at all for this compound.

Frequently asked questions

What is FOXO4-DRI researched for?+

Selectively clearing senescent cells, studied across cartilage, vascular, pulmonary, and endocrine aging models in preclinical research.

How does FOXO4-DRI work?+

It is designed to disrupt the interaction between FOXO4 and p53 inside senescent cells, which redirects p53 toward triggering apoptosis in those specific cells.

Is FOXO4-DRI FDA-approved?+

No, it is a research tool compound with no approved indication and is sold for research use only.

Is this proven in real disease models, or just theoretical?+

Real effects in actual mouse models across multiple contexts — including restoring tissue function in aged tissue and reducing senescent cell buildup in conditions like keloid scarring. Genuinely active research, not purely theoretical.

Looking for something specific, or placing a wholesale order? Send us a DM or email.